Dr. Todd Suscovich, Chief Technology Officer, leads the implementation and further development and of the Systems Serology platform at SeromYx, with a focus on expanding the use of this technology beyond the Infectious Disease space.
Prior to joining SeromYx, his research broadly focused on how molecular events affect both the induction and regulation of the immune response during autoimmunity and infection and how these various pathways and underlying mechanisms can be manipulated to prevent/treat infection and disease. Since 2012, he has worked closely with Dr. Galit Alter at the Ragon Institute of MGH, MIT, and Harvard, leading the development and optimization of the Systems Serology platform, using this technology to identify antibody features and functions that are associated with protection from HIV infection.
Recognizing the broad applicability of this platform in identifying correlates of protection in infection and vaccination beyond HIV, he spearheaded the adaptation and utilization of the Systems Serology technology across a broad range of globally relevant pathogens and diseases including tuberculosis, malaria, RSV, Ebola virus, Zika virus, and pertussis. Todd holds a Bachelor of Science in Molecular Biology from the University of Pittsburgh and a doctorate in Virology from Harvard Medical School.